Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
76.66
+0.33 (0.43%)
At close: Dec 5, 2025, 4:00 PM EST
76.54
-0.12 (-0.16%)
After-hours: Dec 5, 2025, 7:59 PM EST
0.43%
Market Cap 13.64B
Revenue (ttm) 1.11B
Net Income (ttm) -203.88M
Shares Out 177.91M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,234,069
Open 76.17
Previous Close 76.33
Day's Range 74.77 - 77.86
52-Week Range 31.36 - 104.32
Beta n/a
Analysts Strong Buy
Price Target 80.00 (+4.36%)
Earnings Date Nov 4, 2025

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 2,400
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for TEM stock is "Strong Buy." The 12-month stock price target is $80.0, which is an increase of 4.36% from the latest price.

Price Target
$80.0
(4.36% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Is Tempus AI the Next Big Artificial Intelligence Stock to Buy?

Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies.

15 hours ago - The Motley Fool

Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Tempus AI, Inc. (TEM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

2 days ago - Seeking Alpha

Why Tempus AI Stock Soared This Week

Two Ark Invest ETFs added Tempus AI stock to their holdings last Friday. A BTIG analyst sees significant upside to Tempus AI stock.

7 days ago - The Motley Fool

Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Piper Sandler 37th Annual Healthcar...

17 days ago - Business Wire

Tempus AI: Opportunity To Build Position

Tempus AI has pulled back with the broader AI sector, presenting a renewed buying opportunity after strong Q3 results. TEM's Q3 sales surged 85% to $334 million, largely driven by the Ambry acquisitio...

20 days ago - Seeking Alpha

Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and bei...

21 days ago - Business Wire

Tempus AI, Inc. (TEM) Presents at Stifel 2025 Healthcare Conference Transcript

Tempus AI, Inc. ( TEM) Stifel 2025 Healthcare Conference November 13, 2025 10:00 AM EST Company Participants James Rogers - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel,...

22 days ago - Seeking Alpha

Tempus AI: Great Buying Opportunity On Recent Weakness

Tempus AI stands out as a leader in healthcare AI, showing strong execution and robust Q3 results despite recent stock volatility. TEM reported 85% revenue growth, expanding gross margins, and solid p...

22 days ago - Seeking Alpha

Tempus AI: A Good Bet For The Future Of Health Care

Tempus AI remains a buy as its data set, testing volumes, and financial results continue to show robust growth. TEM's Genomics segment drives strong revenue growth, with oncology and hereditary testin...

23 days ago - Seeking Alpha

Tempus AI: First Positive EBITDA, Huge TAM - Yet The Stock Isn't A Buy

Tempus AI is building a strong moat in healthcare AI with vast clinical/genomic datasets and robust infrastructure, driving high-growth potential. TEM achieved its first positive adjusted EBITDA in Q3...

25 days ago - Seeking Alpha

Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says

BTIG analyst Mark Massaro reiterated a Buy rating for Tempus AI, Inc. (NASDAQ:TEM) with a price target of $96 following the third-quarter FY25 earnings beat.

4 weeks ago - Benzinga

Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presen...

4 weeks ago - Business Wire

3 Growth Stocks to Invest $1,000 in Right Now

Several companies offer turnkey access to AI data centers, but only Nebius Group is being called the Amazon Web Services of artificial intelligence. AI isn't replacing doctors and other caregivers, bu...

Other symbols: NBISVRT
4 weeks ago - The Motley Fool

Tempus AI, Inc. (TEM) Q3 2025 Earnings Call Transcript

Tempus AI, Inc. ( TEM) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eric Lefkofsky - ...

4 weeks ago - Seeking Alpha

Tempus Reports Third Quarter 2025 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

4 weeks ago - Business Wire

Tempus to Participate in the Stifel 2025 Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference o...

5 weeks ago - Business Wire

Tempus to Report Third Quarter 2025 Financial Results on November 4

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on...

6 weeks ago - Business Wire

Why Tempus AI Stock Raced More Than 5% Higher Today

There was nothing artificial about the share price boost enjoyed by artificial intelligence (AI) specialist Tempus AI (TEM 5.29%). The company, which concentrates on applying AI functionalities to dru...

6 weeks ago - The Motley Fool

Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed study in...

6 weeks ago - Business Wire

Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therap...

Other symbols: WHWK
7 weeks ago - Business Wire

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presen...

7 weeks ago - Business Wire

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Pr...

2 months ago - Business Wire

Tempus AI's $100 Breakout — Billionaire Cliff Asness Reaps 60% Windfall

Tempus AI Inc (NASDAQ:TEM) has become one of 2025's most dramatic comeback stories. The stock soared past $100 this week, marking a new 52-week high and sending the market buzzing about the AI-powered...

2 months ago - Benzinga

Why Tempus AI Stock Was Motoring Higher This Week

What a difference a week can make on the stock market. Next-generation healthcare tech company Tempus AI's (TEM 1.56%) stock was doing quite well, thank you very much, over the past few days, in contr...

2 months ago - The Motley Fool

Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution.

2 months ago - Business Wire